NASDAQ · GPCR
Structure Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GPCR: Nov 5, 2026
Structure Therapeutics Inc. American Depositary Shares is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.51. The reported EPS for the same quarter last year was $-0.37.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.51 | $-0.36 | $-0.59 | 5 |
| Dec 2026 | $-0.51 | $-0.32 | $-0.61 | 5 |
| Mar 2027 | $-0.48 | $-0.37 | $-0.59 | 2 |
| Jun 2027 | $-0.50 | $-0.42 | $-0.59 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews- Zacks · Oct 27, 7:53 AM EDTBuy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsLilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
- Zacks · Oct 21, 9:20 AM EDTHow Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
- Zacks · Oct 19, 9:15 AM EDTHow Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.
- Zacks · Oct 12, 11:24 AM EDTNovo Down 11% in a Month: How Should Investors Approach the Stock Now?NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
- Zacks · Oct 8, 7:31 AM EDTLLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?LLY's recent dip reflects valuation and competition concerns, but strong GLP-1 demand, pipeline growth and diversification support its long-term outlook.
- Zacks · Sep 30, 8:17 AM EDTCan Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
- Zacks · Sep 23, 9:11 AM EDTCan Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
- Zacks · Sep 17, 11:08 AM EDTLLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
- Zacks · Sep 17, 10:30 AM EDTNovo Falls 5% in a Week: How Should Investors Approach the Stock Now?NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
- Zacks · Sep 14, 10:37 AM EDTWill Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- Zacks · Sep 8, 9:23 AM EDTNovo Nordisk's Semaglutide Meets Goal in Pediatric Obesity StudyNVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Structure Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.